Gerard M.J. Bos

9.0k citations

134 papers · 4.7k indexed · 2 hit papers · h-index 34

Hematology top 0.5%
Rheumatology top 0.5%
Immunology top 2%
Oncology top 5%
Molecular Biology top 10%

Co-authors: Henk J. Blom Martin den Heijer Wilfred T.V. Germeraad W.B.J. Gerrits Pieter H. Reitsma Frits R. Rosendaal Jan P. Vandenbroucke Ernest Briët
Topics: Immune Cell Function and Interaction (42 papers)T-cell and B-cell Immunology (26 papers)Hematopoietic Stem Cell Transplantation (25 papers)
Cited by: Internal Medicine Hematology Rheumatology
Journals: New England Journal of Medicine The LancetSHILAP Revista de lepidopterología
Partner nations: Netherlands United States Belgium

In The Last Decade

Gerard M.J. Bos

131 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis

1996 819 citations Martin den Heijer, Henk J. Blom et al. profile →
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

2021 262 citations Ying Gong, Roel G. J. Klein Wolterink et al. profile →

Peers

Countries citing papers authored by Gerard M.J. Bos

Since Specialization

Citations

This map shows the geographic impact of Gerard M.J. Bos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerard M.J. Bos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerard M.J. Bos more than expected).

Fields of papers citing papers by Gerard M.J. Bos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerard M.J. Bos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerard M.J. Bos. The network helps show where Gerard M.J. Bos may publish in the future.

Co-authorship network of co-authors of Gerard M.J. Bos

This figure shows the co-authorship network connecting the top 25 collaborators of Gerard M.J. Bos. A scholar is included among the top collaborators of Gerard M.J. Bos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerard M.J. Bos. Gerard M.J. Bos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma 2024 ·Immunogenetics ·(unknown),(unknown),(unknown),C.E.M. Voorter,Gerard M.J. Bos,Lotte Wieten	2
2	NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody 2024 ·Molecular Therapy ·Ying Gong,Wilfred T.V. Germeraad,Xulin Zhang,(unknown),Bo Li,(unknown),(unknown),Marion J. Gijbels,(unknown),Birgit L. M. G. Gijsbers,(unknown),Gerard M.J. Bos,Lei Zheng,Roel G. J. Klein Wolterink	14
3	Polymorphic differences within HLA‐C alleles contribute to alternatively spliced transcripts lacking exon 5 2022 ·HLA ·(unknown),(unknown),Mathijs Groeneweg,Gerard M.J. Bos,Marcel G.J. Tilanus,Christina E.M. Voorter,Lotte Wieten	6
4	Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma 2022 ·HemaSphere ·Pieter Sonneveld,Sonja Zweegman,Michèle Cavo,Kazem Nasserinejad,Annemiek Broijl,(unknown),Luděk Pour,Sandra Croockewit,Paolo Corradini,Francesca Patriarca,(unknown),(unknown),Gerard M.J. Bos,Roman Hájek,Maria Teresa Petrucci,Paula F. Ypma,(unknown),Monique C. Minnema,Mario Boccadoro	12
5	Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma 2021 ·Blood Advances ·Kristine A. Frerichs,Monique C. Minnema,Mark‐David Levin,Annemiek Broijl,Gerard M.J. Bos,Marie José Kersten,Tuna Mutis,Christie P.M. Verkleij,Inger S. Nijhof,(unknown),Saskia K. Klein,Sonja Zweegman,Pieter Sonneveld,Niels W.C.J. van de Donk	27
6	Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors 2020 ·Annals of Hematology ·Catharina Van Elssen,Gwendolyn Van Gorkom,(unknown),Peter A. von dem Borne,Ellen Meijer,Lotte Wieten,Gerard M.J. Bos	7
7	HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS 2017 ·Data Archiving and Networked Services (DANS) ·Monique C. Minnema,Kazem Nasserinejad,Bouke P. C. Hazenberg,Ute Hegenbart,L. Noens,Paula F. Ypma,Sonja Zweegman,Lidwine W. Tick,Annemiek Broijl,(unknown),Gerard M.J. Bos,(unknown),Pieter Sonneveld,Stefan Schönland	1
8	Ascorbic acid serum levels are reduced in patients with hematological malignancies 2016 ·PubMed ·Mirelle J.A.J. Huijskens,Will K. W. H. Wodzig,Mateusz Walczak,Wilfred T.V. Germeraad,Gerard M.J. Bos	78
9	Permitting patients to pay for participation in clinical trials: the advent of the P4 trial 2016 ·Medicine Health Care and Philosophy ·David Shaw,Guido de Wert,Wybo Dondorp,David Townend,Gerard M.J. Bos,Michel van Gelder	5
10	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology 2015 ·Haematologica ·Bouke P. C. Hazenberg,Alexandra Croockewit,Bronno van der Holt,Sonja Zweegman,Gerard M.J. Bos,(unknown),Reinier Raymakers,(unknown),Edo Vellenga,P. Wijermans,Peter A. von dem Borne,M. H. van Oers,Okke de Weerdt,(unknown),H M Lokhorst,(unknown)	16
11	Potency of Both Human Th1 and NK Helper Cell Activation is Determined by IL-12p70-Producing PAMP-Matured DCs 2015 ·Journal of Interferon & Cytokine Research ·(unknown),Catharina Van Elssen,(unknown),Birgit L.M.G. Senden-Gijsbers,Wilfred T.V. Germeraad,Gerard M.J. Bos,Joris Vanderlocht	8
12	Medical Students Perceive Better Group Learning Processes when Large Classes Are Made to Seem Small 2014 ·PLoS ONE ·Juliëtte Hommes,Onyebuchi A. Arah,Willem de Grave,Lambert Schuwirth,Albert Scherpbier,Gerard M.J. Bos	27
13	Systemic G-CSF attenuates cerebral inflammation and hypomyelination but does not reduce seizure burden in preterm sheep exposed to global hypoxia–ischemia 2013 ·Experimental Neurology ·Reint K. Jellema,Valéria Lima Passos,Daan R. M. G. Ophelders,Tim G. A. M. Wolfs,Alex Zwanenburg,(unknown),Maria Nikiforou,Jennifer J.P. Collins,Elke Kuypers,Gerard M.J. Bos,H.W.M. Steinbusch,Joris Vanderlocht,Peter Andriessen,Wilfred T.V. Germeraad,Boris W. Kramer	25
14	Expression of Tumor-Associated Differentiation Antigens, MUC1 Glycoforms and CEA, in Human Thymic Epithelial Cells: Implications for Self-Tolerance and Tumor Therapy 2007 ·Cancer Research ·(unknown),(unknown),Marco Thio,Gerard M.J. Bos,Bruno Kyewski,Wilfred T.V. Germeraad	66
15	Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial 2006 ·Blood ·Martin den Heijer,Huub P J Willems,Henk J. Blom,W.B.J. Gerrits,Marco Cattaneo,Sabine Eichinger,Frits R. Rosendaal,Gerard M.J. Bos	193
16	Oral anticoagulant treatment with coumarin derivatives does not influence plasma homocysteine concentration 2006 ·European Journal of Internal Medicine ·Huub P J Willems,Martin den Heijer,W.B.J. Gerrits,Leon J. Schurgers,(unknown),Henk J. Blom,Gerard M.J. Bos	1
17	Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC 2006 ·Cytotherapy ·(unknown),(unknown),Birgit L.M.G. Senden-Gijsbers,Wilfred T.V. Germeraad,Gerard M.J. Bos	13
18	Hyperhomocysteinemia and Venous Thrombosis 1998 ·Seminars in Thrombosis and Hemostasis ·Gerard M.J. Bos,Martin den Heijer	23
19	Variability of the Methionine Loading Test: No Effect of a Low Protein Diet 1996 ·Annals of Clinical Biochemistry International Journal of Laboratory Medicine ·Martin den Heijer,Gerard M.J. Bos,Ingeborg A. Brouwer,W.B.J. Gerrits,Henk J. Blom	11
20	Vergaderen. Verhoofsing en parlementarisering 1989 ·Amsterdams Sociologisch Tijdschrift ·(unknown),Gerard M.J. Bos	1

About Gerard M.J. Bos

Gerard M.J. Bos is a scholar working on Hematology, Immunology and Internal Medicine, having authored 134 papers that have together received 4.7k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (42 papers), T-cell and B-cell Immunology (26 papers) and Hematopoietic Stem Cell Transplantation (25 papers). The work is most often cited by research in Internal Medicine (606 citations), Hematology (1.5k citations) and Rheumatology (1.3k citations). Gerard M.J. Bos has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Henk J. Blom, Martin den Heijer, Wilfred T.V. Germeraad, W.B.J. Gerrits, Pieter H. Reitsma, Frits R. Rosendaal, Jan P. Vandenbroucke, Ernest Briët, Ted Koster and Lotte Wieten. Their work appears in journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact